France
Meddenovo Drug Design is a pioneering company in the realm of AI-driven drug discovery, founded in 2023 and headquartered in France. Specializing in the design of cyclic peptide therapeutics, Meddenovo combines AI technologies and molecular modeling to tackle previously undruggable targets with precision.
The company’s specialized technology platform is designed specifically for cyclic peptides, a promising class in pharmaceutical research due to their high binding affinities, stability, and specificity. The platform uniquely generates designs from scratch, requiring no prior experimental data, and enhances the cell permeability of peptides, marking a significant breakthrough in the field.
Meddenovo recently secured a Seed Round investment on 01 January 2025 from Invest 101, underscoring investor confidence in its potential to revolutionize drug discovery. The company is dedicated to making drug discovery more reliable and accessible, aiming to reduce failure rates and fast-track innovative medicines to market.
